Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-arm companion study of darbepoetin alfa in myelodysplastic syndromes
2013-000727-13Phase 3Completed
- Sponsor
- Amgen
- Start
- Aug 2013
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of darbepoetin alfa in myelodysplastic syndrome (MDS), sponsored by Amgen. Primary endpoint: Subject incidence of treatment-emergent adverse events. Started Aug 2013; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2013-000727-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000727-13.